Cronos Group Inc. (CRON)
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
Cronos: Strong Q1 Earnings Driven By International Cannabis Sales
Cronos reported strong Q1 performance with record level revenue. International sales are driving growth and the Canadian markets are showing improvement. The company is set to acquire CanAdelaar in the Netherlands which will increase its international operations and revenue potential.
Cronos Group Q1 Earnings Call Highlights
Cronos Group NASDAQ: CRON reported record first-quarter 2026 net revenue and gross profit, with management pointing to growth in Israel, gains for its Spinach brand in Canada and continued international expansion as key drivers of the quarter.
Cronos Group (CRON) Q1 Earnings Meet Estimates
Cronos Group (CRON) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.02 per share a year ago.
Cronos: Geographic Expansion Backed By A Strong Balance Sheet
Cronos remains a Strong Buy, supported by robust fundamentals, international expansion, and a depressed $1B valuation with $784M in cash. CRON's acquisition of CanAdelaar and expansion into Europe and Australia position it for accelerated growth and margin improvement over the next 24-36 months. GrowCo's completed capacity expansion and 70% flower volume increase in 2026 are expected to drive top-line and EBITDA margin gains.
3 Canadian Marijuana Stocks Today's Stock Market That Could Soon Run
The cannabis industry is in another pivotal time where consistent changes are being made. Laws and regulations have been passed across the country that have aided in the further development of industry. For most marijuana stock investors, this is the area where shareholders tend to focus. Investors know that a company is doing well, or is working towards a significant goal, which can all lead to profitability. There are different sectors and markets to pay attention to.
Eni's Cronos Development May Add New Gas Volumes to Europe From 2027
E considers moving ahead with the Cronos gas project off Cyprus, which could supply natural gas to Europe by 2027.
Riding the Marijuana Reclassification Wave: 3 Stocks to Watch in 2026
Marijuana's potential move to Schedule III could reshape cannabis economics, putting CRON, VFF and TLRY in focus for 2026 investors.
Cronos: A Standout Balance Sheet Among Its Peers
Cronos Group operates in a highly competitive industry but has a marked advantage over its peers owing to its vastly superior balance sheet. This superiority is a result of a 2019 investment by Altria of $1.8 billion. CRON has experienced consistent cash burn and deep losses since 2019 as it has built and adapted its operations to the newly legalized adult-use cannabis industry in Canada.
Are Medical Stocks Lagging Cronos Group (CRON) This Year?
Here is how Cronos Group (CRON) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
Cronos Group Plans Strategic Europe Expansion: How to Play the Stock?
CRON's planned CanAdelaar acquisition boosts its push into the Dutch adult-use cannabis market and highlights its strengthening international momentum.
Cronos Just Bought Europe's Top Cannabis Producer — Is This the Catalyst Investors Have Waited 5 Years For?
For years, North American cannabis investors have endured a brutal hangover.
